Floatz logo

Pucotenlimab

PD-1 Inhibitor

Zhejiang Provincial People's Hospitalmonoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the PD-1 Inhibitor cohort.

Asset / SponsorPhaseRating
Serplulimab
Fujian Cancer Hospital
Phase 2CCC
Regorafenib
Peking Union Medical College Hospital
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Guangzhou Medical University
Phase 1/2CC
Iparomlimab
Guangzhou Medical University
Phase 1/2CC
Irinotecan
Zhejiang Provincial People's Hospital
Phase 1/2CC

View all 15 →

Same molecule, other indications

Pucotenlimab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
rectal carcinomaDormant
B
Indicative ·
59 / 100
View asset →
rectum adenocarcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →